bluebird bio, Inc.
(NASDAQ : BLUE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.35%242.451.5%$876.05m
MRNAModerna, Inc. 5.05%150.070.0%$811.34m
VRTXVertex Pharmaceuticals, Inc. 0.31%282.661.9%$481.31m
GILDGilead Sciences, Inc. -0.29%61.631.0%$474.01m
REGNRegeneron Pharmaceuticals, Inc. -0.33%589.202.6%$470.12m
NVAXNovavax, Inc. 10.83%57.0075.7%$441.68m
ILMNIllumina, Inc. 1.66%187.423.3%$341.44m
SNSSSunesis Pharmaceuticals, Inc. -1.03%3.840.7%$268.43m
BIIBBiogen, Inc. 1.25%206.481.8%$241.04m
BNTXBioNTech SE 4.21%155.380.0%$195.04m
CRSPCRISPR Therapeutics AG 3.29%62.770.6%$165.36m
BMRNBioMarin Pharmaceutical, Inc. 0.73%83.484.2%$117.04m
EXASEXACT Sciences Corp. 2.31%40.3017.7%$93.03m
IOVAIovance Biotherapeutics, Inc. 3.08%11.380.0%$90.82m
TECHBio-Techne Corp. 0.41%348.054.5%$89.98m

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.